Scientech Research LLC Buys Shares of 15,377 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Scientech Research LLC purchased a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 15,377 shares of the biotechnology company’s stock, valued at approximately $374,000.

Other large investors have also made changes to their positions in the company. ARK Investment Management LLC raised its position in Arcturus Therapeutics by 16.3% during the second quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock valued at $47,847,000 after purchasing an additional 275,315 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Arcturus Therapeutics by 22.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after buying an additional 286,546 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Arcturus Therapeutics by 250.1% during the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after buying an additional 396,505 shares in the last quarter. Granahan Investment Management LLC lifted its position in shares of Arcturus Therapeutics by 12.9% during the 4th quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock worth $14,200,000 after buying an additional 51,504 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Arcturus Therapeutics by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 186,310 shares of the biotechnology company’s stock valued at $5,874,000 after buying an additional 2,369 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

NASDAQ:ARCT opened at $22.03 on Monday. Arcturus Therapeutics Holdings Inc. has a one year low of $17.52 and a one year high of $45.00. The firm’s 50 day simple moving average is $20.91 and its 200 day simple moving average is $26.58. The company has a market cap of $593.31 million, a PE ratio of -5.63 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. The business had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same period in the prior year, the business posted ($1.98) earnings per share. Equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.6 EPS for the current year.

Analysts Set New Price Targets

ARCT has been the subject of a number of research reports. HC Wainwright increased their target price on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Finally, Leerink Partners began coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They set an “outperform” rating and a $70.00 price target for the company. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Arcturus Therapeutics presently has an average rating of “Buy” and a consensus target price of $71.40.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.